A share price of Aclaris Therapeutics Inc [ACRS] is currently trading at $1.95, up 2.63%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACRS shares have gain 5.98% over the last week, with a monthly amount drifted -4.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wedbush started tracking the stock with Outperform rating on May 28, 2025, and set its price target to $8. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $20 on December 23, 2024. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to Outperform for this stock on November 19, 2024, and upped its price target to $7. In a note dated November 19, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $2 to $7.
Aclaris Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $5.17. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.95 at the most recent close of the market. An investor can expect a potential return of 451.28% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
Trailing Twelve Months sales for Aclaris Therapeutics Inc [NASDAQ:ACRS] were 16.79M which represents -35.76% decline. Gross Profit Margin for this corporation currently stands at 0.24% with Operating Profit Margin at -8.73%, Pretax Profit Margin comes in at -8.02%, and Net Profit Margin reading is -8.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.71, Equity is -0.96 and Total Capital is -0.9. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9167 points at the first support level, and at 1.8833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9667, and for the 2nd resistance point, it is at 1.9833.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aclaris Therapeutics Inc [NASDAQ:ACRS] is 3.88. Further, the Quick Ratio stands at 3.88, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 12.58, the price to book ratio is 1.60.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased.
